Evidence map›Paper›PMID 30552739›Full record

ArticleCancer medicine2019

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer.

Alexander J Lin, Pamela Samson, Todd DeWees, Lauren Henke, Thomas Baranski, Julie Schwarz, John Pfeifer, Perry Grigsby, Stephanie Markovina

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. BRAFWorld journal of surgery · 2020
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander J LinDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.ORCID 0000-0002-6971-7187
Pamela SamsonDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Todd DeWeesDivision of Biomedical Statistics and Informatics, Mayo Clinic, Scottsdale, Arizona.
Lauren HenkeDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Thomas BaranskiDivision of Endocrinology, Metabolism and Lipid Research, Department of Internal Medicine, Washington University, St. Louis, Missouri.
Julie SchwarzDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
John PfeiferAlvin J Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri.
Perry GrigsbyDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.
Stephanie MarkovinaDepartment of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes.

methodsIn patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes.

resultsA total of 231 patients had archived formalin-fixed, paraffin-embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6-82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22-0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET-negative and either MAPK(dpERK)-positive or pAKT-positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5-11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3-6.0).

conclusionCharacterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.

Indexed as

AdolescentAdultAgedAged, 80 and overChildFemaleHumansMaleMiddle AgedMitogen-Activated Protein KinasesMutationNeoplasm Recurrence, LocalPPAR gammaProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-retBRAF protein, humanMitogen-Activated Protein KinasesPPAR gammaPPARG protein, humanProto-Oncogene Proteins B-rafProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-retRET protein, humanAKTBRAFMAPKMEKPPARRETthyroid cancertissue array analysis

Identifiers

PMID30552739
PMCPMC6346248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.